_____________________________
Neurotech International Ltd
ABN 73 610 205 402
Level 14, 191 St Georges Terrace
Perth, Western Australia 6060 www.neurotechinternational.com
Anjuli Sinniah
Adviser, Listings Compliance (Perth)
ASX Compliance Pty Ltd
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000
Via Email: [email protected] [email protected]
TRADING HALT
Pursuant to Listing Rule 17.1, Neurotech International Limited (ASX: NTI) (“the Company”) requests a
trading halt for it’s securities for pre-open on Monday 25 September 2017. The trading halt is
requested pending the announcement by the Company of a progress update on the independent US
clinical trial of Mente Autism.
The Company is not aware of any reason why a trading halt should not be granted.
The Company’s securities are to remain in trading halt until the earlier of the commencement of
normal trading on Wednesday 27 September 2017 and when the progress update announcement is
released to the market.
-ends-
About Neurotech
Neurotech International Limited is a medical device and solutions company incorporated in Australia
and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s
primary mission is to improve the lives of people with neurological conditions, with a vision of
becoming the global leader in home-use and clinical neurotechnology solutions that are both
accessible and affordable. Through flagship device Mente Autism and its associated platform,
NTI Price at posting:
16.5¢ Sentiment: Hold Disclosure: Held
